Literature DB >> 19030859

Clinical efficacy of vorinostat in a patient with essential thrombocytosis and subsequent myelofibrosis.

Jin Lee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 19030859     DOI： 10.1007/s00277-008-0640-3

Source DB:  PubMed          Journal:  Ann Hematol        ISSN： 0939-5555            Impact factor:   3.673


× No keyword cloud information.
  7 in total

1.  Efficacy of vorinostat in a murine model of polycythemia vera.

Authors:  Hajime Akada; Saeko Akada; Ajeet Gajra; Alicia Bair; Stephen Graziano; Robert E Hutchison; Golam Mohi
Journal:  Blood       Date:  2012-03-09       Impact factor: 22.113

Review 2.  Therapy of myelofibrosis (excluding JAK2 inhibitors).

Authors:  Alessandro Rambaldi
Journal:  Int J Hematol       Date:  2010-02-24       Impact factor: 2.490

Review 3.  Targeting JAK2 in the therapy of myeloproliferative neoplasms.

Authors:  Mamatha M Reddy; Anagha Deshpande; Martin Sattler
Journal:  Expert Opin Ther Targets       Date:  2012-02-17       Impact factor: 6.902

4.  A phase II study of vorinostat (MK-0683) in patients with primary myelofibrosis and post-polycythemia vera myelofibrosis.

Authors:  Christen L Andersen; Nana B Mortensen; Tobias W Klausen; Hanne Vestergaard; Ole W Bjerrum; Hans C Hasselbalch
Journal:  Haematologica       Date:  2014-01       Impact factor: 9.941

Review 5.  Deactylase inhibition in myeloproliferative neoplasms.

Authors:  Sridurga Mithraprabhu; George Grigoriadis; Tiffany Khong; Andrew Spencer
Journal:  Invest New Drugs       Date:  2010-12-03       Impact factor: 3.850

6.  Epigenetic abnormalities in myeloproliferative neoplasms: a target for novel therapeutic strategies.

Authors:  John Mascarenhas; Nitin Roper; Pratima Chaurasia; Ronald Hoffman
Journal:  Clin Epigenetics       Date:  2011-07-09       Impact factor: 6.551

Review 7.  Epigenetic therapy in myeloproliferative neoplasms: evidence and perspectives.

Authors:  Alessandro M Vannucchi; Paola Guglielmelli; Alessandro Rambaldi; Costanza Bogani; Tiziano Barbui
Journal:  J Cell Mol Med       Date:  2009-06-11       Impact factor: 5.310
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.